Abstract:Background: Breast cancer has the highest incidence rate and causes the most fatalities among all female cancers worldwide. Triple-negative breast cancer (TNBC) is known for its strong invasiveness and higher rates of recurrence. In this research, we aimed to identify MIR4435-2HG as a promising long non-coding RNA (lncRNA) biomarker and therapeutic target for TNBC. Methods: Utilizing clinicopathological information and transcriptome data from The Cancer Genome Atlas (TCGA) database, we assessed the clinical relevance of MIR4435-2HG in breast cancer through univariate and multivariate COX regression, receiver operating characteristic (ROC) analysis, as well as Kaplan-Meier survival analysis. To investigate the biological role of MIR4435-2HG in TNBC, we conducted gene set enrichment analysis (GSEA), as well as Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Additionally, we constructed and validated a nomogram to predict disease-free survival (DFS). Both the R package "pRRophetic" and the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm were employed to forecast the sensitivity to different therapeutics between the high- and low-MIR4435-2HG groups. We employed single-cell RNA sequencing analysis and tumor microenvironment infiltration analysis to investigate the potential involvement of MIR4435-2HG in the TNBC tumor microenvironment. Cellular biological behaviors were assessed utilizing CCK-8, transwell assays, and wound-healing assays. Furthermore, we performed RNA-seq, qRT-PCR, and western blotting analyses to elucidate and confirm the specific mechanisms underlying the role of MIR4435-2HG in TNBC. Results: In our study, we have identified MIR4435-2HG as a significant diagnostic and prognostic factor for TNBC. We observed that MIR4435-2HG is widely expressed and might have a significant impact on the reshaping of the TNBC tumor microenvironment. Patients with TNBC in the high-MIR4435-2HG group may show reduced sensitivity to cisplatin, doxorubicin, and gemcitabine and have an increased propensity for immune escape. Knockdown of MIR4435-2HG inhibits cancer-associated fibroblasts (CAFs) activation. Notably, MIR4435-2HG predominantly enhances the migratory and invasive capabilities of TNBC cells through the epithelial-mesenchymal transition (EMT) process. Mechanistically, we validated that MIR4435-2HG activates the JNK/c-Jun and p38 non-classical MAPK signaling pathway in TNBC cells. Conclusions: Our findings highlight the significant potential of MIR4435-2HG as a highly promising biomarker for TNBC. Targeting MIR4435-2HG could represent an appealing therapeutic approach for TNBC.

mir-101-3p is a key regulator of tumor metabolism in triple negative breast cancer targeting AMPK.

Mir-143-3p Targeting LIM Domain Kinase 1 Suppresses the Progression of Triple-Negative Breast Cancer Cells.

Mir-433 Inhibits Breast Cancer Cell Growth Via the MAPK Signaling Pathway by Targeting Rap1a

FOXCUT Regulates the Malignant Phenotype of Triple-Negative Breast Cancer Via the Mir-337-3p/anp32e Axis

Regulation of Cancerous Progression and Epithelial-Mesenchymal Transition by Mir-34C-3p Via Modulation of MAP3K2 Signaling in Triple-Negative Breast Cancer Cells.

Mir-143-5p Suppresses Breast Cancer Progression by Targeting the HIF-1-related GLUT1 Pathway

Energy Stress-activated AMPK Phosphorylates Snail1 and Suppresses Its Stability and Oncogenic Function

Mir-409-3p Suppresses Breast Cancer Cell Growth and Invasion by Targeting Akt1

Regulation of AMPK-related Glycolipid Metabolism Imbalances Redox Homeostasis and Inhibits Anchorage Independent Growth in Human Breast Cancer Cells

Mir-331-3p Suppresses Cell Proliferation in TNBC Cells by Downregulating NRP2

Inhibition of Mirna-34A Promotes Triple Negative Cancer Cell Proliferation by Promoting Glucose Uptake

AMP-activated Protein Kinase: a Potential Therapeutic Target for Triple-Negative Breast Cancer.

Negative Regulation of Bmi-1 by AMPK and Implication in Cancer Progression.

MIR4435-2HG: A novel biomarker for triple-negative breast cancer diagnosis and prognosis, activating cancer-associated fibroblasts and driving tumor invasion through EMT associated with JNK/c-Jun and p38 MAPK signaling pathway activation

Tumor-promoting Properties of Mir-8084 in Breast Cancer Through Enhancing Proliferation, Suppressing Apoptosis and Inducing Epithelial–mesenchymal Transition

The Micrornas Mir-200B-3p and Mir-429-5p Target the LIMK1/CFL1 Pathway to Inhibit Growth and Motility of Breast Cancer Cells

Overexpression of miR-181a regulates the Warburg effect in triple-negative breast cancer

Identification of Mir-101-3p Targets and Functional Features Based on Bioinformatics, Meta-Analysis and Experimental Verification in Hepatocellular Carcinoma.

Mir-30b-5p Promotes Proliferation, Migration, and Invasion of Breast Cancer Cells Via Targeting ASPP2.

PTP1B Markedly Promotes Breast Cancer Progression and is Regulated by Mir-193A-3p

Clinical Value of Mir-101-3p and Biological Analysis of Its Prospective Targets in Breast Cancer: A Study Based on the Cancer Genome Atlas (TCGA) and Bioinformatics.